NASDAQ$ESTA

Establishment Labs Holdings Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Reported record first-quarter financial results and raised full-year guidance.

Establishment Labs reported a record first quarter with worldwide sales of $30.3 million, a 24% increase year-over-year. The company raised its full-year 2021 revenue guidance to a range of $118 million to $122 million.

  • First quarter worldwide sales reached $30.3 million, a 24% increase year-over-year and a new quarterly record.
  • 2021 guidance increased to a new range of $118 million to $122 million, reflecting a 39% to 44% increase over 2020.
  • First quarter operating expenses decreased by 4% compared to the first quarter of 2020, totaling $22.2 million.
  • The company maintained a strong cash balance of $78.0 million as of March 31, 2021.

Headline financials

Total Revenue

$30.3M

Previous: $24.5M+23.9%
EPS (adj)

-$0.29

Previous: -$0.79+63.3%
Capital Expenditures

-$804K

Previous: -$687K-17.0%
Free Cash Flow

-$7.75M

Previous: -$18.4M+58.0%
Net Income

-$6.95M

Previous: -$17.8M+60.9%
Operating Income

-$2.1M

Previous: -$7.71M+72.8%
Gross Profit

$20.1M

Previous: $15.5M+29.8%
Cash & Equivalents

$78M

Previous: $93.6M-16.7%
Total Assets

$152M

Previous: $168M-9.5%
Stock-Based Comp

$1.76M

No prior period

Revenue & EPS history

Establishment Labs · Revenue · Quarterly

$30.3M

Q1 2021+23.9%vs Q1 2020
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

Establishment Labs raised its full year 2021 revenue guidance to a new range of $118 million to $122 million, which is an annual growth rate of 39% to 44%.

Tailwinds

  • Commercial launch of Motiva Flora tissue expander in Europe on track.
  • Timelines for US and China market entry remain unchanged.
  • Delivered record first quarter revenue of $30.3 million, which was up 24% from the first quarter of 2020 and 13% sequentially from the fourth quarter of 2020
  • Preparing for the commercial launch of our Motiva Flora tissue expander in Europe this summer
  • Regulatory and commercial timelines to begin selling Motiva implants in the U.S. and Chinese markets are progressing as planned

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

+1.5%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+2.4%

Avg return

30 days after

56%

18 / 32 earnings

Positive

+22.5%

Q3 2025

Best reaction

-26.0%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-4.3%+2.9%
Q4 2025-1.9%+5.0%-20.1%
Q3 2025+22.5%+37.0%+43.2%
Q1 2025+4.9%+5.1%+14.2%
Q4 2024+17.9%+28.1%+12.1%
Q3 2024-5.2%-13.2%-10.0%
Q2 2024+3.4%+20.6%+23.5%
Q1 2024+5.4%+4.2%-10.8%
Q4 2023+15.1%+19.6%+28.2%
Q3 2023-26.0%-36.1%-31.7%
Q2 2023-8.4%-12.0%-12.2%
Q1 2023+1.8%-1.6%-1.9%
Q4 2022+7.2%+10.3%+0.3%
Q3 2022-7.7%+11.1%+27.1%
Q2 2022-3.0%+1.3%-0.4%
Q1 2022-10.5%-10.1%+2.3%
Q4 2021+3.3%+1.6%+11.5%
Q3 2021-10.6%-14.3%-15.2%
Q2 2021+6.0%-3.7%-3.1%
Q1 2021-0.6%-1.8%+8.9%
Q4 2020+0.4%-6.8%+9.5%
Q3 2020+8.9%-0.4%+22.6%
Q2 2020+6.2%+7.3%+9.3%
Q1 2020+2.9%+0.5%+15.3%
Q4 2019+4.5%-16.4%+0.4%
Q3 2019-0.3%+0.5%+7.8%
Q2 2019-5.2%-10.6%-10.2%
Q1 2019+1.5%-0.3%-15.9%
Q4 2018-1.9%-4.9%-15.2%
Q3 2017+10.3%+4.5%-6.2%
Q3 2018+10.3%+4.5%-6.2%
Q2 2018-2.7%-2.9%-3.4%
Q4 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro